Breast Cancer Clinical Trial
Study of 124I-NM404 in Advanced Solid Malignancies
The purpose of this study is to assess the use of investigational compound 124I-NM404 for accurate detection and characterization of a wide variety of solid primary and metastatic malignancies anywhere in the body.
124I-NM404 is a new investigational agent being developed to better identify local tumors and cancerous tumors using imaging technologies such as positron emission tomography (PET) scans. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. 124I-NM404 is only taken up by the cancer cells, not the normal cells. Compared to traditional methods such as CT (computed tomography) or MRI (Magnetic resonance imaging), 124I-NM404 may help physicians more accurately see and evaluate cancerous tumors. This agent has been safely studied in animals and a limited number of human patients with lung cancer. This study is being done to determine the best dose to use and to fully evaluate the images that result from using this new agent.
Diagnosis of advanced solid malignancy.
Allowed tumor types: triple negative breast, prostate, colorectal, gastric, ovarian, pancreatic, esophageal, soft tissue sarcoma, and head & neck cancer
Disease must be at least 1cm in diameter
Brain metastasis must be stable for at least one month.
ECOG performance status 0-2
Anticipated survival less than 5 years, as per the treating physician
Skin lesions only
Chemotherapy or radiotherapy within 1 week
Residual toxicities of grade 2 or greater from prior therapy
Adequate organ function as per specified laboratory parameter
Platelet count > or = to 75,000/uL
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Madison Wisconsin, 53792, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.